NervGen Pharma's higher R&D and administrative costs widen Q3 2026 net loss
NGEN•
NGEN•NervGen Pharma reported a third-quarter net loss of CAD 6.41 million, compared with CAD 4.72 million a year earlier, as research and development and administrative costs increased. Cash and cash equivalents totaled CAD 80.12 million at September 30.
NervGen Pharma reported a third-quarter net loss of CAD 6.41 million for the period ended September 30, 2026, compared with CAD 4.72 million a year earlier. Higher research and development and general and administrative costs widened the loss, partly offset by warrant-derivative gains.
Research and development expenses reached CAD 7.9 million, primarily reflecting costs to initiate the Phase 3 NVG-291 trial in chronic tetraplegia. Nine-month net income was CAD 2.47 million, primarily driven by noncash gains on warrant derivatives related to US-dollar-denominated warrants. Cash and cash equivalents totaled CAD 80.12 million at September 30, supported by the May public offering.